Literature DB >> 169729

Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa.

S D Davis.   

Abstract

Mouse protection tests were carried out with four antibiotics and six strains of Pseudomonas aeruginosa. All strains were susceptible to all four antibiotics by an in vitro test. A heavier bacterial inoculum increased the mean effective dose of gentamicin and tobramycin, but not polymyxin B. Second and third doses of gentamicin in the mouse protection test made little change in the mean effective dose. In the mouse protection tests, tobramycin was the most active antibiotic if the results were analyzed in terms of the therapeutic index or ratio of toxicity to efficacy. Colistimethate was poorly inactive in vivo. Polymyxin B was most active on an absolute basis but also was the most toxic. One strain of Pseudomonas was classified as resistant to gentamicin in vivo although it was susceptible in vitro. Strains of Pseudomonas that were uniformly susceptible to antibiotics in vitro were not uniformly susceptible in the mouse protection test to low doses of antibiotic.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 169729      PMCID: PMC429259          DOI: 10.1128/AAC.8.1.50

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Antibiotics for Pseudomonas aeruginosa sepis: inadequate proof of efficacy.

Authors:  S D Davis; A Iannetta; R J Wedgwood
Journal:  J Infect Dis       Date:  1971-07       Impact factor: 5.226

2.  Letter: Interpretation of in vivo tests of susceptibility to antibiotics.

Authors:  S D Davis
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

3.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

4.  Relative antagonism in vitro of calcium in serum to the bactericidal activities of gentamicin and tobramycin on Pseudomonas aeruginosa.

Authors:  S D Davis; A Iannetta
Journal:  Chemotherapy       Date:  1973-10       Impact factor: 2.544

5.  Exotoxins of Pseudomonas aeruginosa. I. Factors that influence the production of exotoxin A.

Authors:  P V Liu
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

6.  Effect of salt concentration on the apparent in-vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin.

Authors:  A A Medeiros; T F O'Brien; W E Wacker; N F Yulug
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

7.  Microbiologic studies related to bacterial resistance to gentamicin.

Authors:  M J Weinstein; C G Drube; E L Moss; J A Waitz
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Butirosin compared with gentamicin in vitro and in vivo.

Authors:  C L Heifetz; J A Chodubski; I A Pearson; C A Silverman; M W Fisher
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

9.  Comparative activity of sisomicin, gentamicin, kanamycin, and tobramycin.

Authors:  J A Waitz; E L Moss; C G Drube; M J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

10.  Dissociation between results of in vitro and in vivo antibiotic susceptibility tests for some strains of Pseudomonas aeruginosa.

Authors:  S D Davis
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  16 in total

1.  Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers.

Authors:  Shu J Lam; Neil M O'Brien-Simpson; Namfon Pantarat; Adrian Sulistio; Edgar H H Wong; Yu-Yen Chen; Jason C Lenzo; James A Holden; Anton Blencowe; Eric C Reynolds; Greg G Qiao
Journal:  Nat Microbiol       Date:  2016-09-12       Impact factor: 17.745

Review 2.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

3.  Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.

Authors:  Jürgen B Bulitta; Jenny C Yang; Liliana Yohonn; Neang S Ly; Silvia V Brown; Rebecca E D'Hondt; William J Jusko; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

4.  Relationship between gentamicin susceptiblity criteria and therapeutic serum levels for Pseudomonas aeruginosa in mouse infection model.

Authors:  T I Nicas; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

5.  Determinants of the efficacy of tobramycin therapy against isogenic nonmucoid and mucoid derivatives of Pseudomonas aeruginosa PAO1 growing in peritoneal chambers in mice.

Authors:  N M Kelly; E G Rawling; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Experimental keratitis due to Pseudomonas aeruginosa: model for evaluation of antimicrobial drugs.

Authors:  S D Davis; J W Chandler
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

7.  Comparative nephrotoxicity of gentamicin and tobramycin in rats.

Authors:  D N Gilbert; C Plamp; P Starr; W M Bennet; D C Houghton; G Porter
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

8.  Comparison of 5-episisomicin (Sch 22591), gentamicin, sisomicin, and tobramycin in treatment of experimental Pseudomonas infections in mice.

Authors:  R V Goering; C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

Review 9.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Comparison of activity of sisomicin and gentamicin in mouse protection tests with gram-negative bacilli.

Authors:  B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.